GSK has stopped (PDF) development of one of the lead programs from its $2.1 billi | GSK has stopped development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 ...

and the company states that 40% of the world’s children receive a GSK vaccine each year. A key product for the company is Shingrix (recombinant zoster vaccine), which is a vaccine that protects ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance for the year, citing lower-than-expected demand. The company said it’s now expecting a low single-digit fall in vaccine sales this ...

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s ...

GSK shares fell on Wednesday after the group's vaccine sales continued to disappoint in the third quarter. The drugmaker saw weaker-than-expected demand for its respiratory syncytial virus (RSV ...

The Advisory Committee on Immunization Practices (ACIP) recommends a single dose of zoster vaccine for immunocompetent adults 60 years of age and older, based on the results of this study ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

(Reuters) -GSK (GSK) on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third ...